TXG News and Press, 10x Genomics Inc. From 02/25/23

Summary PacBio's fourth quarter numbers were ugly, but that was expected as the company prepares for the launch of its next generation of long-read sequencers and its entry into short-read sequencing. The Revio long-read sequencer offers another significant step up in throughput and cos...

Delivers on full year production and cost guidance; exits the year with liquidity of $622 million (All amounts expressed in U.S. Dollars unless otherwise stated) TORONTO, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX:...

10x Genomics to Present at the 43rd Annual Cowen Healthcare Conference PR Newswire PLEASANTON, Calif. , Feb. 22, 2023 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a life sciences leader focused on mastering biology to advance human health, today announced th...

10x Genomics ( NASDAQ: TXG ) is up 10% in Thursday morning trading after Street firm reacted positively to the company's Q4 2022 results and 2023 guidance. The life science technology company beat on the top and bottom lines . While 10x Genomics ( TXG ) provided 2023 reven...

10x Genomics ( NASDAQ: TXG ) is trading 10% higher after the company posted better-than-expected Q4 result, helped by higher consumables revenue in the Americas and EMEA. Q4 GAAP EPS of -$0.15 beat by $0.17, while revenue of $156.2M (+8.9% Y/Y) beats by $8.03M. Gross marg...

10x Genomics, Inc. (TXG) Q4 2022 Earnings Conference Call February 15, 2023, 04:30 PM ET Company Participants Cassie Corneau - Head, Investor Relations & Strategic Finance Serge Saxonov - Chief Executive Officer & Co-Founder Justin McAnear - Chief Financial Off...

10x Genomics press release ( NASDAQ: TXG ): Q4 GAAP EPS of -$0.15 beats by $0.17 . Revenue of $156.2M (+8.9% Y/Y) beats by $8.03M . 2023 Financial Guidance 10x Genomics expects full year 2023 revenue to be in the range of $580 million to $600 million vs $613.96M co...

10x Genomics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Outlook for 2023 PR Newswire Q4 2022 revenue growth of 9% and FY 2022 revenue growth of 5% over the corresponding periods of 2021 PLEASANTON, Calif. , Feb. 15, 2023 /PRN...

Summary Singular Genomics Systems is a unique opportunity to invest in a commercially-viable startup at the forefront of a rapidly expanding field. The company has adequate funding to maintain its current level of commercialization and sales activity for a few years. Capital gains c...

10x Genomics ( NASDAQ: TXG ) is scheduled to announce Q4 earnings results on Wednesday, February 15th, after market close. The consensus EPS Estimate is -$0.20 (-25.0% Y/Y) and the consensus Revenue Estimate is $148.17M (+3.3% Y/Y). Over the last 1 year, TXG has beaten EPS e...